About this document
Combined Metabolomics and Transcriptomics Approach by a5k39pro52 is a document available to read on EtoBox.
This study investigates the effects of IL-6 blockade on amyotrophic lateral sclerosis (ALS) using metabolomics and transcriptomics in a mouse model. The findings indicate that the IL-6 antagonist MR16-1 did not improve clinical outcomes and was associated with accelerated weight loss and adverse alterations in lipid metabolism. Overall, the results suggest that IL-6 blockade may have limited therapeutic benefits in ALS despite its role in inflammation.
- Author
- a5k39pro52
- Language
- EN